| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5463116 | NOVARTIS | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
Oct, 2012
(11 years ago) | |
| US5488150 | NOVARTIS | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them |
Jan, 2013
(11 years ago) | |
| US6641841 | NOVARTIS | Tablet composition |
Nov, 2017
(6 years ago) | |
| US6844008 | NOVARTIS | Tablet composition |
Nov, 2017
(6 years ago) | |
| US6559188 | NOVARTIS | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
Sep, 2020
(3 years ago) | |
| US6878749 | NOVARTIS | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
Sep, 2020
(3 years ago) | |
Starlix is owned by Novartis.
Starlix contains Nateglinide.
Starlix has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Starlix are:
- US5463116
- US5488150
- US6641841
- US6844008
- US6559188
- US6878749
Starlix was authorised for market use on 22 December, 2000.
Starlix is available in tablet;oral dosage forms.
Starlix can be used as use as a blood glucose-lowering agent, use for treatment of diabetes, particularly type 2 diabetes.
The generics of Starlix are possible to be released after 15 September, 2020.
Drugs and Companies using NATEGLINIDE ingredient
Market Authorisation Date: 22 December, 2000
Treatment: Use as a blood glucose-lowering agent; Use for treatment of diabetes, particularly type 2 diabetes
Dosage: TABLET;ORAL
STARLIX family patents
